Espoo, Finland

Petteri Lyytinen


Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Petteri Lyytinen

Introduction

Petteri Lyytinen is an accomplished inventor based in Espoo, Finland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compositions that target cancer treatment. His work is characterized by a focus on innovative solutions that address critical health challenges.

Latest Patents

One of Petteri Lyytinen's notable patents is a pharmaceutical composition of darolutamide. This invention relates to a pharmaceutical composition for oral administration, specifically in the form of a tablet. The composition comprises darolutamide or a pharmaceutically acceptable salt thereof as an active ingredient. Darolutamide is recognized as a potent androgen receptor (AR) modulator, which is useful in treating cancer, particularly AR-dependent cancers such as prostate cancer, as well as other diseases where AR antagonism is desired.

Career Highlights

Petteri Lyytinen is associated with Orion Corporation, a leading pharmaceutical company in Finland. His role at Orion has allowed him to contribute to groundbreaking research and development in the pharmaceutical sector. His expertise in drug formulation and development has positioned him as a key figure in the industry.

Collaborations

Throughout his career, Petteri has collaborated with talented professionals, including Susanna Ilmonen and Juha Lintunen. These collaborations have fostered an environment of innovation and have led to advancements in pharmaceutical compositions.

Conclusion

Petteri Lyytinen's contributions to the field of pharmaceuticals, particularly through his patent on darolutamide, highlight his commitment to improving cancer treatment. His work at Orion Corporation and collaborations with esteemed colleagues further underscore his impact on the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…